Vargasa S, Ramírez BA, Navarro OG

Language: Spanish
References: 11
Page: 32--42
PDF size: 365.45 Kb.

ABSTRACT

The clinical case of a 52-year-old man is presented, with a pathological history of type 2 diabetes mellitus and systemic arterial hypertension, the two with 3 years of evolution and metabolically decompensated for 8 months of evolution. He started with symptoms suggestive of SARS-CoV-2, which evolved in 2 weeks with increased dyspnea, fever, and left eye edema, for which he received in-hospital management. Control studies were performed, including computed tomography of the chest and skull, the first CO-RADS 5 report (very high suspicion of SARS-CoV-2 infection) with a severity scale due to severe extension; the second reported pneumocephalus in the left temporal fossa, left ocular infectious process, which conditioned proptosis, left intraorbital emphysema with involvement of the optic nerve and erosion of adjacent bone structures, as well as emphysema to the left masticatory space. During his stay, he presented an acute infectious process in the maxillary region, left eye and palate, for which mucormycosis pathology was suspected, and treatment with intravenous amphotericin was started. He required intensive therapy management and surgical intervention derived from the extension of the infection, which affected the brain tissue and generated complications and the death of the patient. Mucormycosis is a low prevalence and rapidly progressive disease caused by fungi of the Mucoraceae family of the Mucorales order. It is the fastest evolving fatal fungal disease in humans. For this reason, timely detection and treatment is of utmost importance for the survival of those affected by this agent.

REFERENCES

1. O’Neill B, Alessi A, George E, Piro J. Disseminated rhinocerebral mucormycosis: a case report and review of the literature. J Oral Maxillofacial Surg. 2006;64:32-3.

2. Méndez-Tovar LJ, Mejía-Mercado JA, Manzano-Gayosso P. Frecuencia de micosis invasivas en un hospital mexicano de alta especialidad. Experiencia de 21 años. Rev Med IMSS. 2016;54(5):581-7.

3. Baldin C, Ibrahim A. Molecular mechanisms of mucormycosis— The bitter and the sweet. PLoS Pathog. 2017; 13(8):1-9.

4. Julián-A, Crespo P. Mucormicosis rinocerebral: reporte de un caso y revisión de la literatura. Rev. Cirugía bucal y maxilofacial. 2020;1(16):22-6.

5. Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am. 2016;30(1):143-63.

6. Penna M, Barahona L, Ruz P, Valdés C. Rinosinusitis fúngica invasiva aguda: Actualización en pacientes adultos y pediátricos. Revista de Otorrinolaringología y Cirugía de Cabeza y Cuello. 2019;79:366-373

7. Pandey A, Bansal V, Asthana AK, Trivedi V, Madan M, Das A. Maxillary osteomyelitis by mucormycosis: report of four cases. Int J Infect Dis. 2011;15(1):66-69.

8. Prado H, Fajardo G, Plowes O, Jimenez C. Mucormicosis rinoorbitaria. Estudio de cohorte de su tratamiento de acuerdo a la extensión de la enfermedad y revisión de su fiisiopatología. Gac Med Mex. 2016;152:770-820.

9. Aguilera Y, Díaz Y, Ortiz L, González O, Lovelle O, Sánchez M. Infecciones bacterianas asociadas a la COVID-19 en pacientes de una unidad de cuidados intensivos. ECIMED. 2020;49(3):1-13.

10. Aguilera Y, Díaz Y, Ramos M. Infecciones bacterianas y fúngicas asociadas a la COVID-19. Medicentro Electrónica. 2021;25(2):315-23.

11. Parra I. COVID-19: Manifestaciones clínicas y diagnóstico. Rev Mex de Transplantes. 2020;9(2):160-6.